Amgen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Amgen and other ETFs, options, and stocks.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

26,700

Employees26,700

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

26,700

Employees26,700

AMGN Key Statistics

Market cap

147.74B

Market cap147.74B

Price-Earnings ratio

34.84

Price-Earnings ratio34.84

Dividend yield

3.31%

Dividend yield3.31%

Average volume

3.29M

Average volume3.29M

High today

$276.50

High today$276.50

Low today

$270.28

Low today$270.28

Open price

$272.14

Open price$272.14

Volume

3.50M

Volume3.50M

52 Week high

$346.85

52 Week high$346.85

52 Week low

$253.30

52 Week low$253.30

AMGN News

TipRanks 12h

Amgen 2025 guidance could miss estimates, says Wells Fargo

Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It models $34.1B in r...

Simply Wall St 5d

Amgen's Upcoming Dividend Will Be Larger Than Last Year's

The board of Amgen Inc. ( ) has announced that it will be paying its dividend of $2.38 on the 7th of March, an increased payment from last year's comparable div...

Benzinga 5d

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation

The Food and Drug Administration approved Amgen Inc‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) for KRAS G12C-mutated metastatic colo...

Analyst ratings

47%

of 34 ratings

Buy

44.1%

Hold

47.1%

Sell

8.8%

More AMGN News

Seeking Alpha 5d

Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a combination regimen for adults with meta...